Attovia Therapeutics, Inc. Common Stock Net Assets
Attovia Therapeutics, Inc. Common Stock net assets. Based on the latest financial reports, Attovia Therapeutics, Inc. Common Stock (ATTO) has net assets worth $112.77 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($128.35 Million) and total liabilities ($15.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Attovia Therapeutics, Inc. Common Stock (ATTO) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $112.77 Million |
| % of Total Assets | 87.86% |
| Annual Growth Rate | 142.86% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of Attovia Therapeutics, Inc. Common Stock (2024–2025)
Net assets of Attovia Therapeutics, Inc. Common Stock from 2024 to 2025. This chart illustrates how Attovia Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See Attovia Therapeutics, Inc. Common Stock balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Attovia Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual net assets of Attovia Therapeutics, Inc. Common Stock from 2024 to 2025. For live market cap and overall valuation, see Attovia Therapeutics, Inc. Common Stock stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $150.79 Million | +142.71% |
| 2024-12-31 | $62.13 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Attovia Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6062700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Attovia Therapeutics, Inc. Common Stock Net Assets Breakdown (December 2025)
Attovia Therapeutics, Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $99.00K | 0.07% |
| Other Components | $261.70 Million | 173.55% |
| Total Equity | $150.79 Million | 100.00% |
Attovia Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Attovia Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fujian Nebula Electronics Co Ltd
SHE:300648
|
$693.68 Million |
|
Sinopec Oilfield Equipment Corp
SHE:000852
|
$693.70 Million |
|
Pilkington Deutschland AG
HM:FDD
|
$693.86 Million |
|
Guangdong Kinlong Hardware Products Co Ltd
SHE:002791
|
$693.91 Million |
|
Vital Energy Inc.
NYSE:VTLE
|
$693.32 Million |
|
Tong Oil Tools
SHE:300164
|
$693.19 Million |
|
Jinxi Axle Co Ltd
SHG:600495
|
$693.04 Million |
|
Beijing Join-Cheer Software Co Ltd
SHE:002279
|
$692.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Attovia Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 62,128,000 to 150,790,000, a change of 88,662,000 (142.7%).
- Net loss of 60,627,000 reduced equity.
- New share issuances of 142,388,000 increased equity.
- Other comprehensive income increased equity by 32,000.
- Other factors increased equity by 6,869,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-60.63 Million | -40.21% |
| Share Issuances | $142.39 Million | +94.43% |
| Other Comprehensive Income | $32.00K | +0.02% |
| Other Changes | $6.87 Million | +4.56% |
| Total Change | $- | 142.71% |
Book Value vs Market Value Analysis
This analysis compares Attovia Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.33x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.52x to 4.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $1.44 | $15.19 | x |
| 2025-12-31 | $3.50 | $15.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Attovia Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -40.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4490.89%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.10x
- Recent ROE (-40.21%) is above the historical average (-52.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | -64.06% | 0.00% | 0.00x | 1.23x | $-46.01 Million |
| 2025 | -40.21% | -4490.89% | 0.01x | 1.10x | $-75.71 Million |
Industry Comparison
This section compares Attovia Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Attovia Therapeutics, Inc. Common Stock (ATTO) | $112.77 Million | -64.06% | 0.14x | $693.44 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Attovia Therapeutics, Inc. Common Stock
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of… Read more